Regaining compliance with Nasdaq's minimum bid price requirement is crucial for Allarity Therapeutics to avoid delisting, which can negatively impact investor confidence and stock liquidity. This development is likely to have a positive short-term impact on the stock price as it removes the risk of delisting.